Historical record - last NADAC effective date: 7/19/2023
Product Information
NORETHIND-ETH ESTRAD 0.5-2.5 is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $1.2701 per EA under NDC 75834012929. Its NADAC has been published 330 times since Apr 12, 2017.
FDA first approved this application on Jun 3, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Norethindrone Acetate and Ethinyl Estradiol market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.0025; .5 mg/1; mg/1
Manufacturer
Nivagen Pharmaceuticals Inc.NDC
75834012929
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
7/19/2023
Active Ingredients
ETHINYL ESTRADIOL; NORETHINDRONE ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA203435FDA Approved
6/3/2016
TE Code
AB
On Market Since
11/25/2016
Price Statistics
The NADAC for NORETHIND-ETH ESTRAD 0.5-2.5 has been published 330 times since Apr 12, 2017, and over the history we have for it it has declined 53.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2701 per EA |
|---|---|
| All-time high | $2.9854 (Oct 16, 2019) |
| All-time low | $0.9724 (Jan 20, 2021) |
| Median price | $1.9214 |
| Average price | $1.9752 |
| Largest weekly change | +124.6% (Apr 21, 2021) |
| Weeks tracked | 330 |
| Tracking since | Apr 12, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
-54.8%
All
-53.6%
Last surveyed Aug 2, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 38% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of NORETHIND-ETH ESTRAD 0.5-2.5?
The current National Average Drug Acquisition Cost (NADAC) for NORETHIND-ETH ESTRAD 0.5-2.5, manufactured by Nivagen Pharmaceuticals Inc., is $1.2701 per EA (NDC 75834012929), effective Aug 2, 2023.
How has the price of NORETHIND-ETH ESTRAD 0.5-2.5 changed over time?
Over the history we have for it, the NADAC for NORETHIND-ETH ESTRAD 0.5-2.5 has declined 53.6%. It has been tracked across 330 weekly CMS publications since Apr 12, 2017.
What are the highest and lowest recorded NADAC prices for NORETHIND-ETH ESTRAD 0.5-2.5?
Since Apr 12, 2017, the NADAC for NORETHIND-ETH ESTRAD 0.5-2.5 has ranged from a low of $0.9724 (Jan 20, 2021) to a high of $2.9854 (Oct 16, 2019), with a median of $1.9214 per EA.
Are there cheaper alternatives to NORETHIND-ETH ESTRAD 0.5-2.5?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FYAVOLV 0.5 MG-2.5 MCG TABLET, is $0.7862 per EA — about 38% below NORETHIND-ETH ESTRAD 0.5-2.5.
Who manufactures NORETHIND-ETH ESTRAD 0.5-2.5?
NORETHIND-ETH ESTRAD 0.5-2.5 (NDC 75834012929) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.